Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

VLA 15

Next Previous
Drug Profile

VLA 15

Alternative Names: Borrelia vaccine - GlaxoSmithKline/Valneva; Lyme borreliosis vaccine - GlaxoSmithKline/Valneva; Lyme-borreliosis-vaccine-Valneva; Lyme-disease-vaccine-GlaxoSmithKline/Valneva; Lyme-disease-vaccine-Valneva; PF-07307405; VLA 15

Latest Information Update: 09 Oct 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Intercell
  • Developer Pfizer; Valneva
  • Class Bacterial vaccines; Lyme disease vaccines; Subunit vaccines; Synthetic vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Lyme disease

Most Recent Events

  • 06 Oct 2025 Valneva plans to launch VLA 15 in Lyme's disease in second half of 2027
  • 21 Jul 2025 Pfizer completes phase III trial in Lyme disease (Prevention, In children, In adolescents) in USA (IM) (NCT05634811)
  • 11 Apr 2025 Adverse events and immunogenicity data from a phase II VLA15-221 trial in Lyme disease (Prevention) presented at the 35th Congress of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID-2025)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top